A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers

Who can take part

• Subjects must be at least 21 years of age or older
• Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus
• At Screening Visit 1 and at Randomization, target ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement
• The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care, prior to the initial screening visit
• The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus
• The target ulcer must be Wagner 1 or 2 grade, extending at least through the dermis or subcutaneous tissue and may involve the muscle provided it is below the malleolus
• The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:; ABI between 0.7 and 1.3; TBI greater or equal to 0.6; TCOM greater or equal to 40 mmHg; PVR: biphasic
• If the potential subject has two or more ulcers, they must be separated by at least 2 cm post debridement. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer
• Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to enrollment
• The potential subject must consent to using the prescribed offloading method for the duration of the study
• The potential subject must agree to attend the weekly study visits required by the protocol
• The potential subject must be willing and able to participate in the informed consent process
• Subjects must be at least 21 years of age or older
• At Screening Visit 1 and at Randomization subjects must have a target ulcer with a minimum surface area of 1 cm2 and a maximum surface area of 20 cm2 measured post-debridement
• The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit
• Nonapplicable in this protocol version
• The affected limb must have adequate perfusion confirmed by vascular assessment. Any of the following methods performed within 3 months of the first screening visit are acceptable:; ABI between 0.7 and ≤ 1.3; TBI ≥ 0.6; TCOM ≥ 40 mmHg; PVR: biphasic
• If the potential subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer
• The potential subject must agree to attend the weekly study visits required by the protocol
• The potential subject must be willing and able to participate in the informed consent process

Who cannot take part

• The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the Pl believes will interfere with wound healing such as biologics (monoclonal antibodies, therapeutic proteins and enzymes, gene therapies, cell therapies, cytokines and growth factors and certain vaccines) - Refer to Appendix N for a list of medications
• The potential subject has a previous partial amputation on the affected foot that results in a deformity that impedes proper offloading of the target ulcer
• The surface area measurement of the Target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC
• Participation in a clinical trial involving treatment with an investigational product within the previous 30 days
• The target ulcer was treated with hyperbaric oxygen therapy (HBOT) or a Cellular, Acellular, Matrix-like Product (CAMP) in the 30 days prior to the initial screening visit
• The potential subject is receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of prednisone per day or equivalent) or cytotoxic chemotherapy or is taking medications that the PI believes will interfere with wound healing such as biologics (monoclonal antibodies, therapeutic proteins and enzymes, gene therapies, cell therapies, cytokines and growth factors and certain vaccines)- Refer to Appendix N for a list of medications
• The surface area measurement of the target ulcer decreases by 20% or more during the active 2-week screening phase: the 2 weeks from the initial screening visit (SV-1) to the TV-1 visit during which time the potential subject received SOC
• Participation in a clinical trial involving treatment with an investigational product within the previous 30 days
• The potential subject was treated with hyperbaric oxygen therapy (HBOT) or CAMP in the 30 days prior to the initial screening visit
• The potential subject's target ulcer is not secondary to diabetes
• The target ulcer is infected, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin
• The target ulcer exposes tendon or bone
• There is evidence of osteomyelitis complicating the target ulcer
• The potential subject has applied topical steroids to the ulcer surface within one month of initial screening
• The potential subject has an acute Charcot foot, or an inactive Charcot foot, which impedes proper offloading of the target ulcer
• The potential subject has end stage renal disease requiring dialysis
• A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments
• A subject has a wound with active or latent infection as determined by the Investigator
• A subject with a disorder that would create unacceptable risk of post-operative complications
• The target ulcer is infected as determined by the Investigator, requires systemic antibiotic therapy, or there is cellulitis in the surrounding skin
• The target ulcer exposes tendon or bone
• There is evidence of osteomyelitis complicating the target ulcer
• The potential subject has applied topical steroids to the ulcer surface within one month of initial screening
• The potential subject has end stage renal disease requiring dialysis
• A potential subject who, in the opinion of the investigator, has a medical or psychological condition that may interfere with study assessments
• A subject has a wound with active or latent infection as determined by the Investigator
• A subject with a disorder that would create unacceptable risk of post-operative complications
• The potential subject has a sensitivity or allergy to ethanol or porcine materials
• The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the initial screening visit
• The potential subject has glycated hemoglobin (HbA1c) greater than or equal to 12% within 3 months of the Randomization visit
• The potential subject is known to have a life expectancy of < 6 months
• Nonapplicable in this protocol version
• Women who are pregnant or considering becoming pregnant within the next 6 months
• The potential subject has a malnutrition indicator score <17 as measured on the Mini Nutrition Assessment
• The potential subject has a sensitivity to ethanol or porcine materials
• The potential subject is known to have a life expectancy of < 6 months
• Nonapplicable in this protocol version
• Women who are pregnant or considering becoming pregnant within the next 6 months
• The potential subject has a malnutrition indicator score <17 as measured on the Mini Nutrition Assessment